Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
J Neurol Sci ; 390: 222-226, 2018 07 15.
Artigo em Inglês | MEDLINE | ID: mdl-29801894

RESUMO

OBJECTIVES: To investigate a possible association between isolated white matter lesions suggestive of demyelinating disease in magnetic resonance imaging (MRI) and patent foramen ovale (PFO) evidence in migraine patients, with or without aura. MATERIALS: 31 migraine patients, 28 females and 3 males, with MRI evidence of white matter lesions suggestive of demyelinating disease according to the Barkhof Criteria. All patients underwent further diagnostics including lumbar puncture, autoimmunity panel and cardiological evaluation to detect the presence of PFO. The mean duration of follow-up was 3.46 years and MIPAV software was used to analyze MRI imaging. RESULTS: 14 of the 31 patients (45%) had PFO. A significant association was found between PFO and migraine with visual aura (p < 0.001). No difference in lesion number, volume or area between patients with and without PFO was found, but the distribution was mainly occipital (p < 0.001) in patients with PFO. The follow-up showed a stationary lesion load in all PFO patients; no infratentorial or spinal cord lesion and no enhancement or corpus callosum lesion was ever detected. At the end of follow-up four patients developed multiple sclerosis: younger age at first MRI and oligoclonal bands were associated risk factors. CONCLUSIONS: Migraine is often one of the main symptoms leading to MRI, and in many cases white matter lesions of unspecific significance are discovered, thus placing demyelinating diseases in the differential diagnosis. Our study underlines the potential pathogenetic role of PFO in generating white matter lesions in migraine patients (45%), particularly those with visual aura and occipital lesions. For this reason, we affirm that PFO represents a cardinal point in the differential diagnosis of suspected demyelinating disease.


Assuntos
Doenças Desmielinizantes/diagnóstico , Forame Oval Patente/diagnóstico , Enxaqueca com Aura/diagnóstico , Adulto , Encéfalo/diagnóstico por imagem , Doenças Desmielinizantes/complicações , Diagnóstico Diferencial , Feminino , Seguimentos , Forame Oval Patente/complicações , Coração/diagnóstico por imagem , Humanos , Masculino , Enxaqueca com Aura/complicações , Enxaqueca sem Aura/complicações , Enxaqueca sem Aura/diagnóstico , Bandas Oligoclonais/líquido cefalorraquidiano , Estudos Retrospectivos , Medula Espinal/diagnóstico por imagem
2.
Biochem Pharmacol ; 154: 303-317, 2018 08.
Artigo em Inglês | MEDLINE | ID: mdl-29803506

RESUMO

Neurodegenerative diseases (NDs) and brain tumors are severe, disabling, and incurable disorders that represent a critical problem regarding human suffering and the economic burden on the healthcare system. Because of the lack of effective therapies to treat NDs and brain tumors, the challenge for physicians is to discover new drugs to improve their patients' quality of life. In addition to risk factors such as genetics and environmental influences, increased cellular oxidative stress has been reported as one of the potential common etiologies in both disorders. Given their antioxidant and anti-inflammatory potential, dietary polyphenols are considered to be one of the most bioactive natural agents in chronic disease prevention and treatment. Despite the protective activity of polyphenols, their inefficient delivery systems and poor bioavailability strongly limit their use in medicine and functional food. A potential solution lies in polymeric nanoparticle-based polyphenol delivery systems that are able to enhance their absorption across the gastrointestinal tract, improve their bioavailability, and transport them to target organs. In the present manuscript, we provide an overview of the primary polyphenols used for ND and brain tumor prevention and treatment by focusing on recent findings, the principal factors limiting their application in clinical practice, and a promising delivery strategy to improve their bioavailability.


Assuntos
Neoplasias Encefálicas/prevenção & controle , Sistemas de Liberação de Medicamentos/métodos , Nanopartículas/administração & dosagem , Doenças Neurodegenerativas/prevenção & controle , Compostos Fitoquímicos/administração & dosagem , Polifenóis/administração & dosagem , Animais , Antioxidantes/administração & dosagem , Antioxidantes/química , Antioxidantes/metabolismo , Neoplasias Encefálicas/metabolismo , Ensaios Clínicos como Assunto/métodos , Humanos , Nanopartículas/química , Nanopartículas/metabolismo , Doenças Neurodegenerativas/metabolismo , Fármacos Neuroprotetores/administração & dosagem , Fármacos Neuroprotetores/química , Fármacos Neuroprotetores/metabolismo , Compostos Fitoquímicos/química , Compostos Fitoquímicos/metabolismo , Polifenóis/química , Polifenóis/metabolismo
3.
Clin Genet ; 93(5): 982-991, 2018 05.
Artigo em Inglês | MEDLINE | ID: mdl-29364500

RESUMO

We recently described a complex multisystem syndrome in which mild-moderate myopia segregated as an independent trait. A plethora of genes has been related to sporadic and familial myopia. More recently, in Chinese patients severe myopia (MYP25, OMIM:617238) has been linked to mutations in P4HA2 gene. Seven family members complaining of reduced distance vision especially at dusk underwent complete ophthalmological examination. Whole-exome sequencing was performed to identify the gene responsible for myopia in the pedigree. Moderate myopia was diagnosed in the family which was associated to the novel missense variant c.1147A > G p.(Lys383Glu) in the prolyl 4-hydroxylase,alpha-polypeptide 2 (P4HA2) gene, which catalyzes the formation of 4-hydroxyproline residues in the collagen strands. In vitro studies demonstrated P4HA2 mRNA and protein reduced expression level as well as decreased collagen hydroxylation and deposition in mutated fibroblast primary cultures compared to healthy cell lines. This study suggests that P4HA2 mutations may lead to myopic axial elongation of eyeball as a consequence of quantitative and structural alterations of collagen. This is the first confirmatory study which associates a novel dominant missense variant in P4HA2 with myopia in Caucasian patients. Further studies in larger cohorts are advisable to fully clarify genotype-phenotype correlations.


Assuntos
Colágeno/genética , Hidroxilação/genética , Miopia/genética , Prolil Hidroxilases/genética , Adolescente , Adulto , Criança , China/epidemiologia , Colágeno/metabolismo , Exoma/genética , Feminino , Estudos de Associação Genética , Predisposição Genética para Doença , Humanos , Masculino , Pessoa de Meia-Idade , Mutação de Sentido Incorreto/genética , Miopia/epidemiologia , Miopia/patologia , Linhagem , Fenótipo , Adulto Jovem
4.
Clin Genet ; 93(1): 138-143, 2018 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-28456002

RESUMO

Neurofibromatosis type 1 (NF1) has long been considered a well-defined, recognizable monogenic disorder, with neurofibromas constituting a pathognomonic sign. This dogma has been challenged by recent descriptions of patients with enlarged nerves or paraspinal tumors, suggesting that neurogenic tumors and hypertrophic neuropathy may be a complication of Noonan syndrome with multiple lentigines (NSML) or RASopathy phenotype. We describe a 15-year-old boy, whose mother previously received clinical diagnosis of NF1 due to presence of bilateral cervical and lumbar spinal lesions resembling plexiform neurofibromas and features suggestive of NS. NF1 molecular analysis was negative in the mother. The boy presented with Noonan features, multiple lentigines and pectus excavatum. Next-generation sequencing analysis of all RASopathy genes identified p.Ser548Arg missense mutation in SOS1 in the boy, confirmed in his mother. Brain and spinal magnetic resonance imaging scans were negative in the boy. No heart involvement or deafness was observed in proband or mother. This is the first report of a SOS1 mutation associated with hypertrophic neuropathy resembling plexiform neurofibromas, a rare complication in Noonan phenotypes with mutations in RASopathy genes. Our results highlight the overlap between RASopathies, suggesting that NF1 diagnostic criteria need rethinking. Genetic analysis of RASopathy genes should be considered when diagnosis is uncertain.


Assuntos
Mutação de Sentido Incorreto , Neurofibromatose 1/genética , Síndrome de Noonan/genética , Proteína SOS1/genética , Nervos Espinhais/metabolismo , Adolescente , Adulto , Saúde da Família , Feminino , Sequenciamento de Nucleotídeos em Larga Escala , Humanos , Masculino , Mães , Neurofibromatose 1/patologia , Síndrome de Noonan/patologia , Fenótipo , Nervos Espinhais/patologia
5.
Stem Cell Res ; 10(1): 85-94, 2013 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-23142801

RESUMO

Neural stem cells (NSCs) raised the hope for cell-based therapies in human neurodevelopmental and neurodegenerative diseases. Current research strategies aim to isolate, enrich, and propagate homogeneous populations of neural stem cells. Unfortunately, several concerns with NSC cultures currently may limit their therapeutic promise. Exhaustion of growth factors and/or their uncontrolled release with burst and fall in their concentration may greatly affect the in vitro behavior of NSCs. In this context, we investigate whether a device containing heparan sulfate (HS), which is a co-factor in growth factor-mediated cell proliferation and differentiation, could potentiate and prolong the delivery of fibroblast growth factor-2 (FGF-2) and thus improve in vitro NSC cultivation. We demonstrated that NSCs cultivated in media with a controlled release of FGF-2 from a polyelectrolyte polymer showed a higher proliferation rate, and reduced apoptosis and senescence. In these experimental conditions NSCs preserve their stemness properties for a longer period of time compared with controls. Also of interest is that cell fate properties are conserved as well. The controlled release of FGF-2 reduced the level of oxidative stress and this is associated with a lower level of damaged DNA. This result may explain the reduced level of senescence and apoptosis in NSCs cultivated in the presence of hydrogel-releasing FGF-2.


Assuntos
Técnicas de Cultura de Células/métodos , Fator 2 de Crescimento de Fibroblastos/farmacologia , Células-Tronco Neurais/efeitos dos fármacos , Animais , Diferenciação Celular/efeitos dos fármacos , Proliferação de Células/efeitos dos fármacos , Células Cultivadas , Eletrólitos/química , Heparitina Sulfato/química , Hidrogel de Polietilenoglicol-Dimetacrilato/química , Cinética , Camundongos , Células-Tronco Neurais/citologia , Polímeros/química
6.
Minerva Pediatr ; 59(1): 13-21, 2007 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-17301720

RESUMO

AIM: Optic pathway gliomas (OPG) are the predominant intracranial tumours associated with neurofibromatosis type 1 (NF1). The aim of this study was to evaluate the prevalence and the outcome of OPG in 200 NF1 patients (122 males and 78 females, aged 1-25 years) followed up to 16 years (mean of 6 years). METHODS: All children were evaluated by a detailed physical, neurological and ophthalmological examination. Fifteen out of 200 (7.5%) of these patients (7 males, 8 females) were identified with evidence of optic pathway tumours. RESULTS: Nine children had symptoms such as endocranial hypertension, seizures, headache; 4 patients only showed anomalies at ophthalmological examination; 2 patients had no symptoms or signs. All children had evidence of optic pathway tumour on magnetic resonance imaging. Three had a prechiasmal tumour, 2 had a chiasmal tumour, 1 had prechiasmal/chiasmal tumour, 2 had a prechiasmal/chiasmal and postchiasmal tumour, 2 had a chiasmal and postchiasmal tumour, 4 had a massive involvement of the optic system, 1 child exhibited a bilateral involvement of the optic nerves with additional impairment of the chiasm. Four patients had partial and/or subtotal spontaneous regression. CONCLUSIONS: Because optic pathway tumours arise in children younger than 6 years of age, all NF1 children should undergo yearly ophtalmologic examination and growth assessment to monitor signs of precocious puberty.


Assuntos
Neurofibromatose 1/epidemiologia , Glioma do Nervo Óptico/epidemiologia , Vias Visuais/patologia , Adolescente , Adulto , Criança , Pré-Escolar , Feminino , Seguimentos , Humanos , Lactente , Hipertensão Intracraniana/epidemiologia , Imageamento por Ressonância Magnética , Masculino , Neurofibromatose 1/patologia , Quiasma Óptico/patologia , Glioma do Nervo Óptico/patologia , Prevalência , Remissão Espontânea , Estudos Retrospectivos , Índice de Gravidade de Doença , Fatores de Tempo
7.
Cell Death Differ ; 12(6): 603-13, 2005 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-15846373

RESUMO

Recent studies suggest a close relationship between cell metabolism and apoptosis. We have evaluated changes in lipid metabolism on permeabilized hepatocytes treated with truncated Bid (tBid) in the presence of caspase inhibitors and exogenous cytochrome c. The measurement of beta-oxidation flux by labeled palmitate demonstrates that tBid inhibits beta-oxidation, thereby resulting in the accumulation of palmitoyl-coenzyme A (CoA) and depletion of acetyl-carnitine and acylcarnitines, which is pathognomonic for inhibition of carnitine palmitoyltransferase-1 (CPT-1). We also show that tBid decreases CPT-1 activity by a mechanism independent of both malonyl-CoA, the key inhibitory molecule of CPT-1, and Bak and/or Bax, but dependent on cardiolipin decrease. Overexpression of Bcl-2, which is able to interact with CPT-1, counteracts the effects exerted by tBid on beta-oxidation. The unexpected role of tBid in the regulation of lipid beta-oxidation suggests a model in which tBid-induced metabolic decline leads to the accumulation of toxic lipid metabolites such as palmitoyl-CoA, which might become participants in the apoptotic pathway.


Assuntos
Carnitina O-Palmitoiltransferase/antagonistas & inibidores , Proteínas de Transporte/farmacologia , Ácidos Graxos/metabolismo , Mitocôndrias Hepáticas/metabolismo , Proteína Agonista de Morte Celular de Domínio Interatuante com BH3 , Cardiolipinas/metabolismo , Carnitina O-Palmitoiltransferase/metabolismo , Proteínas de Transporte/metabolismo , Inibidores de Caspase , Caspases/metabolismo , Permeabilidade da Membrana Celular/efeitos dos fármacos , Células Cultivadas , Citocromos c/metabolismo , Hepatócitos/efeitos dos fármacos , Hepatócitos/metabolismo , Humanos , Malonil Coenzima A/metabolismo , Potenciais da Membrana/efeitos dos fármacos , Proteínas de Membrana/genética , Mitocôndrias Hepáticas/genética , Oxirredução/efeitos dos fármacos , Ligação Proteica , Proteínas Proto-Oncogênicas c-bcl-2/genética , Proteínas Proto-Oncogênicas c-bcl-2/metabolismo , Proteína Killer-Antagonista Homóloga a bcl-2
8.
Cell Death Differ ; 12(1): 65-77, 2005 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-15459751

RESUMO

Marrow stromal stem cells (MSCs) are stem-like cells that are currently being tested for their potential use in cell therapy for a number of human diseases. MSCs can differentiate into both mesenchymal and nonmesenchymal lineages. In fact, in addition to bone, cartilage and fat, it has been demonstrated that MSCs are capable of differentiating into neurons and astrocytes. RB and RB2/p130 genes are involved in the differentiation of several systems. For this reason, we evaluated the role of RB and RB2/p130 in the differentiation and apoptosis of MSCs under experimental conditions that allow for MSC differentiation toward the neuron-like phenotype. To this end, we ectopically expressed either RB or RB2/p130 and monitored proliferation, differentiation and apoptosis in rat primary MSC cultures induced to differentiate toward the neuron-like phenotype. Both RB and RB2/P130 decreased cell proliferation rate. In pRb-overexpressing cells, the arrest of cell growth was also observed in the presence of the HDAC-inhibitor TSA, suggesting that its antiproliferative activity does not rely upon the HDAC pathway, while the addition of TSA to pRb2/p130-overexpressing cells relieved growth inhibition. TUNEL reactions and studies on the expression of genes belonging to the Bcl-2 family showed that while RB protected differentiating MSCs from apoptosis, RB2/p130 induced an increase of apoptosis compared to controls. The effects of both RB and RB2/p130 on programmed cell death appeared to be HDAC- independent. Molecular analysis of neural differentiation markers and immunocytochemistry revealed that RB2/p130 contributes mainly to the induction of generic neural properties and RB triggers cholinergic differentiation. Moreover, the differentiation potentials of RB2/p130 and RB appear to rely, at least in part, on the activity of HDACs.


Assuntos
Diferenciação Celular/fisiologia , Células-Tronco Mesenquimais/fisiologia , Neurônios/citologia , Proteínas/fisiologia , Proteína do Retinoblastoma/fisiologia , Acetilcolinesterase/genética , Acetilcolinesterase/metabolismo , Adenoviridae/genética , Animais , Apoptose/fisiologia , Proteínas de Ciclo Celular/genética , Proteínas de Ciclo Celular/metabolismo , Morte Celular/fisiologia , Diferenciação Celular/efeitos dos fármacos , Proliferação de Células , Células Cultivadas , Inibidor de Quinase Dependente de Ciclina p27 , Proteínas de Ligação a DNA/genética , Fatores de Transcrição E2F , Inibidores Enzimáticos/farmacologia , Expressão Gênica/efeitos dos fármacos , Expressão Gênica/genética , Vetores Genéticos/genética , Inibidores de Histona Desacetilases , Histona Desacetilases/fisiologia , Ácidos Hidroxâmicos/farmacologia , Imuno-Histoquímica , Células-Tronco Mesenquimais/citologia , Células-Tronco Mesenquimais/metabolismo , Proteínas do Tecido Nervoso/genética , Proteínas do Tecido Nervoso/metabolismo , Proteínas de Neurofilamentos/metabolismo , Neurônios/metabolismo , Proteínas/genética , Proteínas/metabolismo , Ratos , Proteína do Retinoblastoma/genética , Proteína do Retinoblastoma/metabolismo , Proteína p130 Retinoblastoma-Like , Fatores de Transcrição/genética , Transfecção , Proteína Supressora de Tumor p53/metabolismo , Proteínas Supressoras de Tumor/metabolismo
9.
Neurology ; 61(7): 988-90, 2003 Oct 14.
Artigo em Inglês | MEDLINE | ID: mdl-14557576

RESUMO

The authors report an Italian family with autosomal-dominant Charcot-Marie-Tooth disease (CMT) in which there were giant axons in the sural nerve biopsy. Linkage to the known CMT2 loci (CMT2A, CMT2B, CMT2D, CMT2F) and mutations in the known CMT2 genes (Cx32, MPZ, NEFL), GAN, NEFM, and CMT1A duplication/HNPP deletion were excluded. This family with CMT and giant axons has a pathologic and genetic entity distinct from classic CMT.


Assuntos
Axônios/patologia , Doença de Charcot-Marie-Tooth/genética , Doença de Charcot-Marie-Tooth/patologia , Adulto , Idoso , Axônios/ultraestrutura , Biópsia , Doença de Charcot-Marie-Tooth/fisiopatologia , Criança , Análise Mutacional de DNA , Eletrodiagnóstico , Feminino , Genes Dominantes , Humanos , Itália , Masculino , Pessoa de Meia-Idade , Linhagem , Nervos Periféricos/patologia , Nervos Periféricos/fisiopatologia , Nervo Sural/patologia , Nervo Sural/ultraestrutura
10.
J Cell Physiol ; 195(2): 220-33, 2003 May.
Artigo em Inglês | MEDLINE | ID: mdl-12652649

RESUMO

Neural stem cells (NSCs) could be very useful for the "cell therapy" treatment of neurological disorders. For this reason basic studies aiming to well characterize the biology of NSCs are of great interest. We carried out a molecular and immunocytochemical analysis of EGF-responsive NSCs obtained from rat pups. After the initial growth of NSCs as floating neurospheres in EGF-containing medium, cells were plated on poly-L-ornithine-coated dishes either in the presence or absence of EGF. We followed cell differentiation and apoptosis for 21 days in vitro and analyzed the expression levels of some genes having a major role in these processes, such as pRB, pRB2/p130, p27, and p53. We observed that EGF impairs neuronal differentiation. Furthermore, in the absence of mitogens, apoptosis, which appeared to proceed through the "p53 network," was significantly lower than in the presence of EGF. The cyclin kinase inhibitor p27, while important for cell cycle exit, seemed dispensable for cell survival and differentiation.


Assuntos
Técnicas de Cultura de Células/métodos , Diferenciação Celular/efeitos dos fármacos , Linhagem da Célula/efeitos dos fármacos , Separação Celular/métodos , Fator de Crescimento Epidérmico/farmacologia , Proteínas do Tecido Nervoso , Proteínas , Transplante de Células-Tronco/métodos , Células-Tronco/metabolismo , Animais , Animais Recém-Nascidos , Apoptose/efeitos dos fármacos , Apoptose/fisiologia , Astrócitos/citologia , Astrócitos/efeitos dos fármacos , Astrócitos/metabolismo , Proteínas Sanguíneas/efeitos dos fármacos , Proteínas Sanguíneas/genética , Proteínas Sanguíneas/metabolismo , Proteínas de Ciclo Celular/efeitos dos fármacos , Proteínas de Ciclo Celular/metabolismo , Diferenciação Celular/fisiologia , Linhagem da Célula/fisiologia , Células Cultivadas , Inibidor de Quinase Dependente de Ciclina p27 , Regulação da Expressão Gênica/efeitos dos fármacos , Regulação da Expressão Gênica/fisiologia , Proteína Glial Fibrilar Ácida/efeitos dos fármacos , Proteína Glial Fibrilar Ácida/genética , Proteína Glial Fibrilar Ácida/metabolismo , Imuno-Histoquímica , Proteínas de Filamentos Intermediários/efeitos dos fármacos , Proteínas de Filamentos Intermediários/genética , Proteínas de Filamentos Intermediários/metabolismo , Nestina , Neurônios/citologia , Neurônios/efeitos dos fármacos , Neurônios/metabolismo , Proteínas Proto-Oncogênicas c-bcl-2/efeitos dos fármacos , Proteínas Proto-Oncogênicas c-bcl-2/genética , Proteínas Proto-Oncogênicas c-bcl-2/metabolismo , RNA Mensageiro/efeitos dos fármacos , RNA Mensageiro/metabolismo , Ratos , Proteína do Retinoblastoma/efeitos dos fármacos , Proteína do Retinoblastoma/genética , Proteína do Retinoblastoma/metabolismo , Proteína p130 Retinoblastoma-Like , Células-Tronco/citologia , Células-Tronco/efeitos dos fármacos , Proteína Supressora de Tumor p53/efeitos dos fármacos , Proteína Supressora de Tumor p53/metabolismo , Proteínas Supressoras de Tumor/efeitos dos fármacos , Proteínas Supressoras de Tumor/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA